GSA Capital Partners LLP Sells 716,698 Shares of Nektar Therapeutics (NASDAQ:NKTR)

GSA Capital Partners LLP lessened its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 77.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 214,245 shares of the biopharmaceutical company’s stock after selling 716,698 shares during the quarter. GSA Capital Partners LLP’s holdings in Nektar Therapeutics were worth $279,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Bank of New York Mellon Corp boosted its holdings in Nektar Therapeutics by 2,822.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 532,663 shares during the period. Nantahala Capital Management LLC lifted its position in shares of Nektar Therapeutics by 66.0% during the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after acquiring an additional 1,634,046 shares in the last quarter. Samlyn Capital LLC bought a new position in shares of Nektar Therapeutics in the second quarter worth $11,728,000. Millennium Management LLC grew its position in shares of Nektar Therapeutics by 56.1% in the second quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after purchasing an additional 1,674,924 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of Nektar Therapeutics during the 2nd quarter valued at $1,037,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Stock Up 4.0 %

Nektar Therapeutics stock opened at $1.05 on Friday. The stock has a market cap of $193.68 million, a price-to-earnings ratio of -1.25 and a beta of 0.61. The business has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $1.31. Nektar Therapeutics has a 52 week low of $0.42 and a 52 week high of $1.93.

Analyst Ratings Changes

Several research analysts have commented on NKTR shares. BTIG Research restated a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research note on Monday, September 30th. Piper Sandler started coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $3.50.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.